Melasma: The Mask of Pregnancy

Clinical Overview

Melasma represents an acquired disorder of cutaneous hyperpigmentation characterized by symmetric, irregular patches of brown or gray-brown discoloration typically affecting the face in sun-exposed distribution patterns. The condition predominantly affects women of reproductive age (peak incidence 40-50 years), with strong associations to pregnancy, oral contraceptive use, and sun exposure. Melasma demonstrates particular predilection for individuals with darker skin phototypes (Fitzpatrick types III-VI), including Hispanic, Mediterranean, Indian, and East Asian populations, with lower prevalence in fair-skinned individuals. The word "melasma" derives from Greek "melas" meaning "black," reflecting the characteristic dark appearance of affected skin. While melasma is benign and does not indicate underlying systemic disease, the condition causes significant cosmetic concerns and psychological distress, particularly in visible facial location affecting appearance and self-perception. Multiple triggering factors including estrogen, ultraviolet radiation, genetic predisposition, and possibly chemical irritants contribute to pathogenesis. Treatment remains challenging, with recurrence common even after successful initial resolution.

Epidemiology

Melasma affects approximately 1-4% of global population with significant geographic variation, reaching 10-35% prevalence in populations with darker skin types in tropical regions. Peak incidence occurs in women aged 40-50 years, with rare presentation before age 20 years. Female-to-male ratio approaches 10:1, with rare male cases typically associated with sun exposure or genetic predisposition. Prevalence is highest in Hispanic populations (35-40% in some regions), followed by Mediterranean, Indian, and Asian populations (15-30%). Pregnancy-related melasma (chloasma gravidarum) develops in 10-40% of pregnant women, with higher incidence in women with darker skin types. Oral contraceptive use increases risk approximately 2-3 fold. Hormone replacement therapy increases risk in some populations. Genetic predisposition appears significant, with positive family history in 35-50% of patients. UV radiation exposure represents critical triggering and perpetuating factor. Certain medications including cosmetic products and possibly antimalarial agents associate with melasma development.

Pathophysiology

Melasma develops through increased melanin production by melanocytes and increased transfer of melanin-containing melanosomes to surrounding keratinocytes, resulting from complex interplay of genetic, hormonal, photobiologic, and possibly chemical factors. Estrogen and progesterone enhance melanin production through upregulation of melanogenic enzymes including tyrosinase and related proteins. Estrogen binds to estrogen receptor alpha on melanocytes and keratinocytes, increasing cAMP levels and downstream signaling driving melanin synthesis. Progesterone similarly enhances melanin production through progesterone receptor signaling. UV radiation, particularly UVA which penetrates deeply into dermis, triggers melanogenesis through p53-mediated pathways and reactive oxygen species (ROS) generation. ROS increase activates stem cell factor (SCF) and endothelin-1 production, further stimulating melanocytes. Genetic factors predispose to melasma through unknown mechanisms, with certain HLA phenotypes and genetic polymorphisms in melanogenic pathways associating with increased risk. The condition demonstrates increased incidence of perivascular lymphocytic infiltration and increased dermal melanophages in affected skin, suggesting chronic inflammatory component. Some propose chemical irritant exposure from cosmetics as contributing trigger. Melanocytes appear enlarged with increased dendrites and increased melanosome production. The distribution typically follows areas of maximal sun exposure and facial anatomy (centrofacial, malar, and mandibular patterns).

Clinical Presentation

Melasma typically presents as symmetric, sharply demarcated patches of brown or gray-brown discoloration affecting the face, particularly affecting cheeks, bridge of nose, forehead, upper lip, and chin in characteristic centrofacial distribution. Lesions may also involve temples, ears, and neck representing photodistribution. The color ranges from light tan to dark brown depending on skin type and depth of pigmentation. Lesions demonstrate irregular borders with gradual fading at periphery rather than sharp demarcation. Melasma remains purely cosmetic with no associated symptoms including pruritus, pain, or systemic manifestations. The skin texture remains normal without atrophy, induration, or erosions. Some patients report that melasma darkens with sun exposure and lightens with sun avoidance. Melasma may be triggered by pregnancy and resolve partially after delivery, though many women experience persistent disease. Estrogen-containing contraceptives and hormone replacement therapy frequently exacerbate or trigger melasma development. The psychological impact frequently exceeds medical severity, with significant distress regarding facial appearance reported by majority of affected patients.

Diagnosis

Diagnosis of melasma is primarily clinical, based on characteristic distribution and appearance of symmetric hyperpigmented patches affecting face in characteristic patterns. Wood's lamp examination (365-nm ultraviolet light) enhances visualization of epidermal melanin deposition, making lesions appear darker and more contrasted against surrounding skin. This technique helps determine whether pigmentation is predominantly epidermal (prominent under Wood's lamp) or dermal (minimal change under Wood's lamp), which influences treatment selection. Melanin predominantly in epidermis responds better to depigmenting treatments than dermal melanin. Reflectance confocal microscopy (RCM) provides non-invasive imaging of melanin distribution within epidermis and dermis. Dermoscopy visualization reveals increased reticular melanin distribution within epidermis. Histopathological examination via punch biopsy demonstrates increased melanin within basal keratinocytes and melanocytes, with variable dermal melanophage infiltration. Direct immunofluorescence is negative, ruling out autoimmune melanocytic disorders. Serologic testing for anti-nuclear antibodies helps exclude systemic lupus erythematosus that can cause facial hyperpigmentation. Serum hormone levels may be evaluated in unclear cases but are not routinely necessary.

Treatment Algorithm

Treatment of melasma remains challenging due to high recurrence rates even after successful initial resolution, necessitating strict sun protection and ongoing maintenance therapy. Strict photoprotection represents cornerstone of therapy, with daily broad-spectrum sunscreen SPF 30+ (or higher) and physical sun avoidance preventing new pigment deposition and limiting treatment efficacy loss. Topical depigmenting agents including hydroquinone 2-4% applied twice daily represent first-line therapy. Hydroquinone 4% concentration demonstrates stronger efficacy but higher risk of irritation and ochronosis (blue-gray discoloration) with prolonged use. Combination therapy with tretinoin 0.05% nightly plus hydroquinone 4% twice daily produces superior efficacy compared to monotherapy. Fluocinolone acetonide 0.01% plus hydroquinone 4% plus tretinoin 0.05% triple combination (Tri-Luma) represents potent combination achieving 75% improvement in 8 weeks. Kojic acid 2% applied twice daily provides milder depigmentation. Alpha-hydroxy acids including glycolic acid 10-15% applied regularly enhance keratinocyte turnover and melanin clearance. Azelaic acid 15-20% applied twice daily demonstrates efficacy particularly for dermal melasma and can prevent irritation associated with hydroquinone. Vitiligo-like depigmentation (ochronosis, rarely confetti-like hypopigmentation) can complicate prolonged hydroquinone use, limiting duration to 3-4 months followed by breaks. Oral tranexamic acid 250-500 mg twice daily administered for 3-6 months achieves improvement in 40-70% of patients through mechanisms including plasmin inhibition and reduction of melanin-stimulating factors. Chemical peels including glycolic acid, salicylic acid, and TCA facilitate epidermal melanin removal. Laser treatment including Q-switched Nd:YAG, alexandrite, and ruby lasers targets melanin with variable results and risk of post-inflammatory hyperpigmentation particularly in darker skin types.

Prognosis

Prognosis for melasma is favorable for treatment response but guarded regarding recurrence, with approximately 40-50% of patients experiencing recurrence within 1 year of stopping treatment. Strict sun protection and ongoing maintenance therapy significantly improve outcomes. Pregnancy-related melasma (chloasma) partially resolves after delivery in 25-50% of patients, with remaining women experiencing persistent disease. Cessation of oral contraceptives or hormone replacement therapy leads to melasma improvement in 25-50% of women. Depigmenting agents including hydroquinone achieve 75% improvement in 8-12 weeks with proper adherence. Combination therapies produce superior results compared to monotherapy. Dermal melasma responds less effectively to topical therapy and may require laser treatment. Post-inflammatory hyperpigmentation and erythema can complicate aggressive treatment approaches, particularly in darker skin types. Most patients require maintenance therapy indefinitely to prevent recurrence.

When to See a Dermatologist

Patients with melasma causing cosmetic concerns should seek dermatology evaluation for appropriate treatment selection. Those with darkly pigmented lesions (suggesting dermal involvement) warrant specialist assessment for optimal therapeutic approach. Women considering laser treatment should consult dermatologists experienced in treating darker skin types to minimize post-inflammatory hyperpigmentation risk.

Frequently Asked Questions

Q: Is melasma dangerous?
A: No, melasma is benign and indicates no increased risk of skin cancer or systemic disease. It is purely a cosmetic concern.

Q: Will melasma go away after pregnancy?
A: Approximately 25-50% of pregnancy-related melasma improves after delivery. Many women experience persistent disease requiring treatment.

Q: Can I prevent melasma if I'm at risk?
A: Strict daily sun protection with broad-spectrum sunscreen SPF 30+ and avoidance of triggering factors including oral contraceptives and estrogen therapy reduce risk substantially.

Q: Can melasma return after treatment?
A: Yes, melasma frequently recurs even after successful treatment, with 40-50% recurrence within one year if sun protection not maintained and maintenance therapy discontinued.

References

  1. Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol. 1995;131(12):1453-1457.
  2. Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4(6):698-710.
  3. Kang HY, Ortonne JP, Picardo M. Cellular and molecular mechanisms in melasma: aetiology and therapeutics. Exp Dermatol. 2010;19(5):382-390.
  4. Gilchrest BA, Blog FB, Szabo G. Effects of aging and chronic sun exposure on melanosomes. J Invest Dermatol. 1979;73(2):142-147.
  5. Estes NC. Melasma. In: Goldsmith LA, Katz SI, Gilchrest BA, et al, editors. Fitzpatrick's Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2012. p. 926-932.
  6. Pandya AG, Hynan LS, Bhore R, et al. Reliability assessment and validation of the modified Melasma Area Severity Index (mMASI) and the Melasma Area and Severity Index (MASI) in estimating Melasma severity. Dermatol Surg. 2011;37(10):1416-1426.
  7. Sarkar R, Patra S, Dasgupta T, et al. Efficacy of tranexamic acid in melasma: a prospective open-label clinical study. Indian J Dermatol Venereol Leprol. 2012;78(5):583-587.
  8. Passeron T, Picardo M. Melasma, a photoaging disorder: pathogenesis and treatment. G Ital Dermatol Venereol. 2018;153(3):305-313.
  9. Ortonne JP. Photoprotective antioxidants and free radicals in human skin: an overview. J Eur Acad Dermatol Venereol. 2002;16(5):532-534.
  10. Vazquez M, Sanchez JL. Dermatology consultation. Puerto Rico Health Sci J. 1998;17(1):59-63.